
    
      This is a single-center, open label, pilot trial of ustekinumab in patients with Primary
      Sj√∂gren's Syndrome (PSS). Up to 15 subjects will receive an infusion loading dose of 6 mg/kg
      of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and
      week 20. Subjects will be followed for 24 weeks.
    
  